Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (111)

« Back to Publications

Point-of-care HIV viral load testing in a community antiretroviral therapy delivery programme: A randomised controlled trial (PHILA).

Dorward J. et al, (2026), PLOS Glob Public Health, 6

Uptake and 24-month Outcomes of Dolutegravir- Versus Lopinavir-based Second-line Antiretroviral Therapy for People With HIV in South Africa: A Retrospective Cohort Study and Emulated Target Trial

Brown JA. et al, (2025), Open Forum Infectious Diseases, 12

The PRINCIPLE randomised controlled open label platform trial of hydroxychloroquine for treating COVID19 in community based patients at high risk

Hobbs FDR. et al, (2025), Scientific Reports, 15

Cost and clinical flow of point-of-care urine tenofovir testing for treatment monitoring among people living with HIV initiating ART in South Africa

Wang M. et al, (2025), Journal of the International AIDS Society, 28

Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration

Nguyen BT. et al, (2025), Journal of Infectious Diseases, 231, e1080 - e1090

Impact of increasing CD4 count threshold eligibility for antiretroviral therapy initiation on advanced HIV disease and tuberculosis prevalence and incidence in South Africa: an interrupted time series analysis

Asare K. et al, (2025), BMJ Global Health, 10

cceptability and perspectives on clinic-based urine tenofovir testing for antiretroviral therapy adherence monitoring: qualitative findings from a randomized controlled trial in South Africa

Bardon AR. et al, (2025)

Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART

Naidoo K. et al, (2025), Southern African Journal of HIV Medicine, 26

Retrospective cohort analysis of antiretroviral therapy initiation timelines and clinical outcomes in adults with HIV and TB disease in KwaZulu-Natal, South Africa

Jansen van Vuuren CJ. et al, (2025), International Journal of STD and AIDS

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Harris V. et al, (2025), The Lancet Infectious Diseases, 25, 68 - 79

Improving quality of interpersonal care in HIV programmes

Tlhaku K. and Dorward J., (2025), The Lancet HIV, 12, e3 - e5

Risk of major adverse cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: emulated target trials using routine, de-identified data from South Africa

Dorward J. et al, (2025)

Uptake and 24-month outcomes of dolutegravir- versus lopinavir-based second-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study and emulated target trial

Brown JA. et al, (2025)

Point-of-care HIV viral load testing in a community antiretroviral therapy delivery programme: a randomised controlled trial (PHILA)

Dorward J. et al, (2025)

Retrospective cohort analysis of antiretroviral therapy initiation timelines and clinical outcomes in adults with HIV and TB disease in KwaZulu-Natal, South Africa

Jansen van Vuuren C. et al, (2025)

Load More

1
2
3
4
5
6
7
...
»